Sector News

After delay, CSL’s $11.7B deal for Vifor poised to close next week

August 7, 2022
Life sciences

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track.

Tuesday, CSL said it had clinched all regulatory clearance needed to go through with its Vifor buy, which is now expected to close next week on Aug. 9, the companies said in a release.

Once the offer is settled, CSL expects to get its hands on more than 97% of Vifor shares. At the same time, CSL plans to have Vifor apply for the delisting of its shares post-close. CSL has also filed an action to cancel remaining publicly held Vifor shares to satisfy Swiss takeover rules.

Alongside news of the looming merger, CSL has tapped GSK veteran Hervé Gisserot to lead the incoming Vifor business as general manager. Gisserot joined Vifor in January and currently serves as the company’s chief commercial officer. He entered the Vifor fold from GSK, where he held several senior vice president roles, including most recently head of pharmaceuticals and vaccines for greater China and intercontinental.

In tandem with the acquisition’s close, Vifor’s current CEO Abbas Hussain will step down in the “coming months,” the companies said.

The $11.7 billion deal will give CSL access to Vifor’s kidney disease and iron deficiency offerings. CSL’s biotech business, CSL Behring, currently depends on its immunoglobulin portfolio, which has struggled during the COVID-19 pandemic thanks to plasma collection hurdles.

Merger aside, it hasn’t all been smooth sailing for Vifor in recent months. Earlier this year, the FDA swatted down Akebia Therapeutics’ chronic kidney disease anemia therapy vadadustat, which Vifor has a license to sell through its Fresenius dialysis facilities and other third-party sites.

Meanwhile, the acquisition hit a snag back in May when CSL said the deal would “take a few more months” beyond its originally proposed closing period of June 2022.

Vifor, in its own statement, said certain antitrust authorities hadn’t delivered a verdict on the potential buyout. At the time, rulings from the U.S. Federal Trade Commission, the European Competition Commission and the Swiss Takeover Board were all still pending, according to the Australia Financial Review.

By Fraiser Kansteiner

Source: fiercepharma.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach